Navigation Links
KICVentures Ramps Up AxioMed Freedom Cervical Disc Manufacturing to Meet OUS Orders and Expand Market Share Rapidly
Date:12/27/2018

AxioMed completed its initial production of the first 60 cervical discs for implantation at its new Boston facility, and is now raising growth capital to ramp up demand for orders already placed, and to have additional inventory to immediately expand market share against inferior ball and socket discs. The capital raise is targeted to qualified private investors with a $50,000 minimum per investor. This sum encourages more participation vs. institutions with deeper pockets because Dr. Chin, Managing Partner and CEO of KICVentures (AxioMed's parent company) believes this disc should have a grass roots success story.

About AxioMed LLC

AxioMed was founded to advance the standard of care for patients with degenerative spine conditions by progressing spine technology beyond fusion and first-generation artificial discs. Led by an experienced surgeon team and utilizing patented viscoelastic polymer technology, AxioMed has developed the next generation of artificial discs. AxioMed completed its U.S. IDE for the Lumbar Disc with over five years of clinical follow-up.

About KICVentures

KICVentures is a private investment company founded in 2005 by Harvard-trained Orthopedic Surgeon & Professor Dr. Kingsley R. Chin, who brings unique experience at the intersection of medicine, business and information technology. KICVentures is equipped with a strong advantage in identifying niche healthcare opportunities, and is headquartered in Boston, Mass.

Read the full story at https://www.prweb.com/releases/kicventures_ramps_up_axiomed_freedom_cervical_disc_manufacturing_to_meet_ous_orders_and_expand_market_share_rapidly/prweb15997208.htm.


'/>"/>
Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved


Related biology news :

1. DFG and Leopoldina: Recommendations on scientific freedom and scientific responsibility
2. Genetic circuit allows both individual freedom, collective good
3. Study shows Hera Therapeutics compound combats HPV types that cause most cervical cancer
4. Clearing cells to prevent cervical cancer
5. Current guidelines underestimate US cervical cancer incidence and older womens risk
6. Radiation therapy for cervical cancer increases risk for colorectal cancer
7. LSUHSC research reveals structure of master regulator and new drug target for autism, cervical cancer
8. International team completes systematic, genomic study of cervical cancer
9. Biocompare Releases Documentary on “What Researchers Need to Know about Antibody Manufacturing”
10. RoosterBio Inc. and Tissue Regeneration Therapeutics Inc. Announce Alliance Around Scale-up Manufacturing of Umbilical Cord Tissue Perivascular Cell Technology
11. ACEA Biosciences Joins Cell Manufacturing Research Initiative to Further Advance Cell Therapy Discovery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/10/2019)... (PRWEB) , ... January 09, 2019 , ... Dr. Beanlands ... Heart Institute in Ottawa, Ontario, Canada. He is also Director of its National ... of Medicine, in the Department of Radiology, and in the Department of Cellular and ...
(Date:1/8/2019)... ... January 07, 2019 , ... Join industry experts Julie Peacock, Client Services at ... on Thursday, January 17, 2019 at 1pm EST. , This webinar will ... clinical trial process. Featured speakers will also present a case study of a leading ...
(Date:1/7/2019)... (PRWEB) , ... January 07, 2019 , ... ... (RWD) and Artificial Intelligence solutions for precision health in oncology and other key ... J.P Morgan’s exclusive meeting of investors, entrepreneurs and executives spanning the entire healthcare ...
Breaking Biology News(10 mins):
(Date:1/4/2019)... ... January 04, 2019 , ... Triangle Insights Group, a premier ... Ted will be joining the firm as a partner. , Ted has ... the pharmaceutical industry. At Triangle Insights, Ted will apply his deep expertise in ...
(Date:1/4/2019)... DIEGO (PRWEB) , ... January 03, 2019 , ... ... at the forefront of oncolytic virus-based immunotherapies for cancer, today announced the founding ... Biotherapeutics to receive critical input and guidance from key leaders in the Immuno-Oncology ...
(Date:12/19/2018)... FREDERICK, Md. (PRWEB) , ... December 19, 2018 ... ... solutions for Life Science, announces the validated release of Limfinity® version 7.1. The ... another important technical offering from RURO as 2018 comes to an end. , ...
(Date:12/18/2018)... ... 18, 2018 , ... Patients with early stages of breast cancer who undergo ... versus whole breast irradiation, a new study suggests. , Patients with early stage breast ... after removal of the cancerous tumor because there is a 30 to 40 percent ...
Breaking Biology Technology: